疏肝解郁汤加减联合黛力新治疗脑梗死后并发抑郁症临床分析

Clinical Analysis of Shugan Jieyu Decoction and Deanxit in the Treatment of Depression after Cerebral Infarction

ES评分 0

DOI
刊名
Journal of International Psychiatry
年,卷(期) 2019, 46(6)
作者
作者单位

汉中市中心医院呼吸内科一病区 ;

摘要
目的:探讨疏肝解郁汤加减联合黛力新治疗脑梗死后并发抑郁症的临床效果。方法:研究主体为脑梗死并发抑郁症患者,总共90例。研究时间为2018年07月--2019年07月。以数字随机表方法,将研究主体分为两组并进行对照研究,包括常规组、研究组,每组各占45例。其中常规组单独采用黛力新予以治疗,而研究组则在服用黛力新的同时予以疏肝解郁汤加减治疗。统计并比较两组临床治疗总体疗效、HAMDA抑郁评分、SDS抑郁评分、用药治疗时间、精神状态复常时间、不良反应。结果:研究组临床治疗总体疗效明显更高,与常规组对比存在明显差异(p<0.05);治疗之前,研究组与常规组HAMD抑郁评分、SDS抑郁评分并无明显差异(p<0.05);治疗1周、2周、3周、4周之后,研究组HAMD抑郁评分、SDS抑郁评分明显更低,与常规组对比存在明显差异(p<0.05),且治疗后HAMD抑郁、SDS抑郁评分评分低于治疗前(p<0.05);研究组用药治疗时间、精神状态复常时间明显更短,与常规组存在明显差异(p<0.05);与常规组比较,研究组不良反应总发生率明显更低,两组之间存在明显差异(p<0.05)。结论:相较于黛力新单独治疗而言,脑梗死后并发抑郁症的患者加用疏肝解郁汤,可获得更高的临床疗效,而且还可以显著减轻患者抑郁程度,缩短用药治疗时间,促使患者精神状态早日恢复正常,最主要的是联合用药方案不良反应少,安全性较高,值得引起临床高度重视并大范围普及、推广。
Abstract
Objective: To explore the clinical effect of Shugan Jieyu Decoction combined with Deanxit in the treatment of depression after cerebral infarction. Methods: 90 patients with cerebral infarction complicated with depression were studied. The study was conducted from July 2018 to July 2019. With the method of digital random table, the subjects of the study were divided into two groups and the control study was conducted, including the routine group and the research group, each of which accounted for 45 cases. The routine group was treated with Deanxit alone, while the research group was treated with Shugan Jieyu Decoction at the same time. The overall clinical efficacy, HAMDA depression score, SDS depression score, medication treatment time, mental state recovery time and adverse reactions were compared between the two groups. Result: The clinical curative effect of the study group was significantly higher than that of the routine group (p < 0.05). Before treatment, there was no significant difference in HAMD depression score and SDS depression score between the study group and the routine group (p < 0.05). After treatment for 1 week, 2 weeks, 3 weeks and 4 weeks, the HAMD depression score and SDS depression score of the study group were obvious. The scores of HAMD depression and SDS depression after treatment were lower than those before treatment (p < 0.05). The treatment time and mental state recovery time of the study group were significantly shorter than those of the routine group (p < 0.05). Compared with the routine group, the total adverse reactions of the study group were significantly shorter (p < 0.05). The incidence was significantly lower, and there was a significant difference between the two groups (p < 0.05). CONCLUSION: Compared with Deanxit alone, Shugan Jieyu Decoction can achieve higher clinical efficacy in patients with depression after cerebral infarction. It can also significantly reduce the degree of depression, shorten the time of medication treatment, and promote the early recovery of patientsmental state. The most important thing is that the combined medication scheme is not effective. With less adverse reactions and higher safety, it deserves to be highly valued and widely popularized in clinic.
关键词
疏肝解郁汤;黛力新;脑梗死;抑郁症;临床疗效;安全性
KeyWord
Shugan Jieyu Decoction; Deanxit; Cerebral infarction; Depression; Clinical efficacy; Safety
基金项目
页码 1070-1072
  • 参考文献
  • 相关文献
  • 引用本文

刘文田*. 疏肝解郁汤加减联合黛力新治疗脑梗死后并发抑郁症临床分析 [J]. 国际精神病学杂志. 2019; 46; (6). 1070 - 1072.

  • 文献评论

相关学者

相关机构